Home/ Stocks/ PRLD

Prelude Therapeutics Incorporated

PRLD XNAS

$4.86 -0.16 (-3.11%) ▼ 15-min delayed

Open

$5.15

High

$5.32

Low

$4.79

Volume

528.3K

Market Cap

$387.06M

About Prelude Therapeutics Incorporated

Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 79 Website →

Key Financials

Period	Revenue	Net Income	EPS
TTM 2025	$12.14M	$-99,498,000	$-1.29
FY 2025	$12.14M	$-99,498,000	$-1.29
Q3 2025	$6.50M	$-19,725,000	$-0.26
Q2 2025	$0	$-31,231,000	$-0.41

Related Market News

No specific coverage for PRLD yet. Check out our latest market news or earnings calendar.

Get PRLD Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Prelude Therapeutics Incorporated.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.